徐珊

研究方向：抗肿瘤药物、心血管药物活性及作用机制研究

电子邮箱：shanxu9891@126.com

简要介绍：主持国家自然科学基金1项，江西省自然科学基金2项，省教育厅科技项目2项，校青年拔尖人才项目1项、校级重点课题和一般课题各1项，近年来以第一或者通讯作者发表SCI论文30余篇，申请中国发明专利10项，授权8项。主持教育部产学研项目、省质量工程、省教改课题5项，校级教改课题2项，校级质量工程项目3项、获江西省教学成果一等奖4项，二等奖1项（排名第一）；2021年获首届江西省高校教师教学创新大赛三等奖，2017-2019年获全国药学类青年教师竞赛特等奖1项（药理组全国仅2人）、一等奖3项，二等奖1项，获中国职业技术师范教师教学竞赛特等奖1项、省青年教师教学竞赛二等奖1项；指导学生参加全国大学生制药工程设计竞赛获二等奖1项，三等奖1项；指导学生获省级比赛20余项；作为班主任所带14制药工程1班获全国活力团支部等荣誉。

代表成果：

1. Wen C, Zhang Y, Lai L, et al. Photothermally Enhanced Cascaded Nanozyme-Functionalized Black Phosphorus Nanosheets for Targeted Treatment of Infected Diabetic Wounds. Adv Healthc Mater. Published online November 17, 2023.  

2. Xie Z, Ruan W, Guo J, et al. T5S1607 identified as a antibacterial FtsZ inhibitor：Virtual screening combined with bioactivity evaluation for the drug discovery. Comput Biol Chem. 2024;108:108006.  

3. Tang S, Sun C, He X, et al. Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)-7-methoxyquinazoline derivatives as dual EGFR/c-Met inhibitors for the treatment of NSCLC. Eur J Med Chem. 2024;263:115939.  

4. Fan D, Zhang H, Duan L, et al. Design, synthesis, and evaluation of antitumor activity of Mobocertinib derivatives, a third-generation EGFR inhibitor. Bioorg Chem. 2024;147:107390.

5. Wang R, Ruan W, Fan D, et al. Virtual Screening and Biological Evaluation of T22306 as a Potent Third-generation EGFR Inhibitor for NSCLC Treatment. Anticancer Agents Med Chem. Published online February 7, 2025.